Seeking to stem a sharp rise in HIV cases among young people, Brazil has become the first country in Latin America to adopt the drug, providing it at no cost in 22 cities in a pilot program.
SÃO PAULO, Brazil — Seeking to stem a sharp rise in HIV cases among young people, Brazil began offering a drug this month that can prevent infection to those deemed at high risk.
Brazil is the first country in Latin America, and among the first in the developing world, to adopt the pill Truvada, under a program known as PrEP, short for pre-exposure prophylaxis, as an integral part of its preventive health care policy.
The blue pill — which drastically reduces the risk of contracting the virus when taken daily — will be made available at no cost to eligible Brazilians at 35 public health clinics in 22 cities during an inaugural phase of the program.
The Brazilian Health Ministry is paying Gilead Sciences, the U.S. manufacturer of the drug, about 75 cents a dose, a fraction of the price users pay in the United States, where the pill sells for upward of $1,600 for a month’s supply.
Most Read Nation & World Stories
- UPDATE: Throw out romaine lettuce from SW Arizona, CDC warns as E. coli spreads
- Democratic party files lawsuit against Russia, Trump campaign, alleging conspiracy to influence the election
- Miss America 2005 marries same-sex partner in Alabama
- Court: Sotomayor shoulder injury worse than first thought
- Student says Confederate flag theft sparked protests
The drug is being rolled out at a crucial time in Brazil, with the country’s health officials particularly alarmed by the rise of the virus among young men and other groups considered at higher risk.
Between 2006 and 2015, the number of AIDS cases in men ages 15-19 almost tripled, to 6.9 cases per 100,000 people. Among men 20-24, the rate almost doubled to 33.1 cases per 100,000, according to U.N.AIDS, a United Nations agency that coordinates HIV prevention policy around the world.
About 48,000 new cases of HIV were reported in Brazil in 2016 and about 14,000 deaths related to AIDS, the agency said.
While the transmission of the virus from mother to child has been significantly reduced, about 1 in 10 men who have sex with men in Brazil have HIV, the agency said.
“Our hope is that with PrEP and other measures we can reduce the rate of new infections,” said Adele Benzaken, the director of the AIDS department at Brazil’s Health Ministry. “But it’s a big challenge.”
PrEP is being made available to prostitutes, transgender people, men who have sex with men, some drug users and people in relationships with partners who have HIV.
Brazil has long been recognized for its strong response to the HIV epidemic. It challenged pharmaceutical companies in the 1990s by producing generic versions of costly antiretroviral drugs, which lowered prices globally. Brazil’s government buys and distributes more condoms than any other country, and in 2013 it started providing antiretroviral therapy free to all HIV-positive adults seeking care.
Proponents of the plan to distribute PrEP say Brazil’s experience will show the economic benefits of investing in prevention.
“With the addition of PrEP, Brazil is using all of the strategies that we recommend,” said Georgiana Braga-Orillard, the director of UNAIDS Brazil. “This is a large-scale operation, and Brazil could become an example to all of Latin America that we need to see an integrated approach.”
Since the U.S. Federal Drug Administration approved Truvada as a prevention drug for HIV in 2012, several countries have sought to make it available and affordable to people at risk of contracting HIV.
For the first year of Brazil’s program, the Health Ministry spent $2.7 million for 3.6 million pills. Screening and additional care will be provided at no cost at public clinics.
Benzaken, the ministry official, said Brazil expected to spend less on this preventive care next year as generic versions of the drug arrive in the market.
“It was a good deal,” she said. “But we need to bring the price down even more.”
She said two pharmaceutical companies, including Mylan, had applied to Brazil’s health regulatory agency, Anvisa, for approval of generic versions of Truvada.
People have grown less concerned about HIV, leading to a decline in the use of condoms, said José Valdez Madruga of the São Paulo Health Secretariat, who was one of the coordinators of a PrEP trial in Brazil carried out before its implementation. The drug provides an additional safeguard.
“With PrEP, it puts the decision in the hands of one person, said Madruga, the head of the secretariat’s AIDS and sexually transmitted disease center. “You don’t need the agreement of the other partner, as with condoms.”
According to a survey in Brazil by the gay-dating app Hornet and U.N.AIDS, 36 percent of respondents said they would probably use PrEP if it were available.
Critics of PrEP have said it incentivizes condomless sex, leading to the spread of other sexually transmitted diseases.
Márcio Pierezan, 29, a patient who participated in the trial, said those fears were overblown. He started taking the pill two years ago.
“It was at a time when four close friends had tested positive for HIV, and I was in an open relationship with someone who had tested positive,” he said. “I was in constant fear that I would be next, even though I used condoms.”
Pierezan says that the pill is as an added protection, but that he never stopped using condoms. “It became part of my routine,” he said. “I take it with coffee in the morning, and it’s been a huge relief for me, my friends, my mother!”